Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 46, Issue 9, Pages 1651-1658Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2005.01.069
Keywords
-
Categories
Ask authors/readers for more resources
OBJECTIVES Stem cell therapy may be useful in chronic myocardial infarction (MI); this is conceivable, but not yet demonstrated in humans. BACKGROUND After acute MI, bone marrow-derived cells improve cardiac function. METHODS We treated 18 consecutive patients with chronic MI (5 months to 8.5 years old) by the intracoronary transplantation of autologous bone marrow mononuclear cells and compared them with a representative control group without cell therapy. RESULTS After three months, in the transplantation group, infarct size was reduced by 30% and global left ventricular ejection fraction (+15%) and infarction wall movement velocity (+57%) increased significantly, whereas in the control group no significant changes were observed in infarct size, left ventricular ejection fraction, or wall movement velocity of infarcted area. Percutaneous transluminal coronary angioplasty alone had no effect on left ventricular function. After bone marrow cell transplantation, there was an improvement of maximum oxygen uptake (Vol(2max), +11%) and of regional F-18-fluor-desoxy-glucose uptake into infarct tissue (+15%). CONCLUSIONS These results demonstrate that functional and metabolic regeneration of infarcted and chronically avital tissue can be realized in humans by bone marrow mononuclear cell transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available